APTARGROUP, INC. (ATR): Results of Operations and Financial Condition
APTARGROUP, INC. (ATR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 atr-20260630x8kexx991.htm EX-99.1 Document Exhibit 99.1 Aptar Reports Second Quarter 2026 Results Crystal Lake, Illinois, July 30, 2026 -- AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing,
How this was made
The 30-second read
Why it matters
Traders can update models using the new Q2 datapoints (sales, adjusted EPS, segment performance, margins) and the explicit Q3 adjusted EPS range, including the assumed effective tax rate range and EUR/USD exchange rate.
Market read
The filing is a direct earnings-and-guidance update with concrete EPS and margin context, plus shareholder return actions and a stated operational improvement narrative.
What to watch
Higher effective tax rate versus prior year and the stated emergency medicine destocking headwind timing could drive volatility if the abatement in Q4 is delayed.
Background
This is an SEC Form 8-K with Exhibit 99.1 reporting Aptar’s Q2 2026 results and providing Q3 2026 adjusted EPS guidance, along with dividend and buyback details.
Ticker impact
Aptar reported Q2 2026 sales of $1.03B, adjusted EPS $1.42, and guided Q3 adjusted EPS to $1.45-$1.53 in an 8-K.
Likely modest near-term repricing around the Q3 adjusted EPS range and tax-rate assumptions, with focus on margin headwinds described.
The filing contains fresh, decision-relevant datapoints: Q2 reported and adjusted EPS, segment growth/mix commentary, and explicit Q3 adjusted EPS guidance plus tax-rate and FX assumptions.
Market effects
Drug delivery and dispensing suppliers may see read-through on demand trends in injectables, consumer healthcare, and closures, plus margin sensitivity to product mix.
Limited direct regional spillover; primarily US-listed large-cap industrial/healthcare supply chain sentiment.
FX and tax-rate assumptions are explicitly referenced, which can matter for cross-border comparability for multinational peers.
Counterpoint
Despite revenue growth, the guidance is only a narrow band and margins are described as impacted by mix and operational factors, so the market may discount the outlook.
Key entities
- public_companyAptarGroup, Inc.
Global drug delivery, dosing, and protection technologies provider reporting Q2 results and issuing Q3 adjusted EPS guidance.
- executiveStephan B. Tanda
President and CEO quoted on Q2 performance and the transition to a new CEO on September 1.
- executiveGael Touya
Named as the incoming CEO assuming the role on September 1.
